Fenofibrate

證據等級: L5

預測適應症: 7 個

Fenofibrate: From Hyperlipidemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Fenofibrate is a fibric acid derivative (PPAR-α agonist) with an established, well-documented use in hyperlipidemia and mixed dyslipidemia. The TxGNN model's top-ranked prediction is Homozygous Familial Hypercholesterolemia (HoFH), but this signal is currently supported by only 1 loosely related clinical trial (testing a different drug) and 11 publications, none of which directly test fenofibrate in HoFH.

Quick Overview

Item	Content
Original Indication	Not recorded in the evidence pack's regulatory fields; fenofibrate's known original use is hyperlipidemia / mixed dyslipidemia (fibrate class), corroborated by the rank-2 prediction rationale
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.91%
Evidence Level	L4
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for fenofibrate (flagged as a High-severity data gap, DG002). Based on known pharmacological class information, fenofibrate is a fibric acid derivative and PPAR-α agonist that activates lipoprotein lipase and lowers apoC-III, reducing triglycerides and raising HDL-C. Its efficacy in hyperlipidemia and mixed (type IIb/III/IV/V) hyperlipoproteinemia is well established — this is directly supported within this same evidence pack by the rank-2 prediction ("hyperlipoproteinemia"), which reaches Evidence Level L1 with multiple completed Phase 3 RCTs.

HoFH, however, is a distinct clinical entity: it is caused by near-complete loss of LDL-receptor function, leading to markedly elevated LDL-C that is largely independent of the triglyceride/HDL-focused PPAR-α pathway fenofibrate acts on. The relationship between fenofibrate's proven original use (TG-lowering in dyslipidemia) and this new predicted indication is therefore indirect at best.

The repurposing rationale captured in the evidence pack states this explicitly: "fenofibrate's PPAR-α/TG pathway has no direct relationship to the pathogenic mechanism of HoFH; clinically it is not part of mainstream HoFH therapy" (mainstream options being statins, PCSK9 inhibitors, lomitapide, or LDL apheresis). Consistent with this, the single retrieved clinical trial (NCT03510715) tests alirocumab, not fenofibrate, in HoFH patients — it overlaps only in target population, not in drug. This prediction should therefore be read as a TxGNN model signal awaiting direct mechanistic or clinical validation, not as an evidence-backed repurposing opportunity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03510715	Phase 3	Completed	18	Evaluated alirocumab (PCSK9 inhibitor), not fenofibrate, in children/adolescents with HoFH on background therapy — relevance limited to population overlap only (grade C)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6593751	1984	Clinical	Pharmacological Research Communications	Fenofibrate 300 mg/day in type II hyperlipoproteinemia (22 patients); one HoFH patient showed the greatest fall in total and LDL cholesterol among all subjects
24734312	2014	PK Study	Pharmacotherapy	Characterized pharmacokinetic interactions of lomitapide (an approved HoFH drug) with fenofibrate and other lipid-lowering agents
24946816	2014	Case series	Internal Medicine Journal	Liver transplantation for HoFH; discusses standard/emerging lipid-lowering therapies as inadequate alone for severe LDL-C elevation
37979722	2024	Review	Indian Heart Journal	States fenofibrate's most definite indication is monotherapy for fasting triglyceride >500 mg/dL to reduce pancreatitis risk, with modest cardiovascular benefit
28437620	2017	Guideline	Endocrine Practice	AACE/ACE dyslipidemia management and cardiovascular disease prevention guideline
2042836	1991	Review	Annals of the NY Academy of Sciences	Reviews pharmacologic/surgical treatment options for dyslipidemic children with familial hypercholesterolemia, including fenofibrate among several agents
35499807	2022	Review	Current Atherosclerosis Reports	Reviews dyslipidemia management in pregnancy; general context, not fenofibrate/HoFH-specific
26432726	2015	Review	Indian Heart Journal	Reviews LDL-C reduction via statins and PCSK9 inhibitors; general background, no fenofibrate/HoFH data
14620392	2003	Review	Pharmacotherapy	Reviews ezetimibe as a cholesterol absorption inhibitor; general background only
9129869	1997	Review	Drugs	Reviews atorvastatin pharmacology and therapeutic potential; general background only

Finland Market Information

Fenofibrate currently holds 0 marketing authorizations in Finland and is not on the market (market_status: 未上市). No product/license records are available in the evidence pack.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data were not available at the time of this evaluation (DG001, Blocking severity — TFDA/label warning data could not be retrieved, which also blocks progression to the S1 safety-review stage).

Conclusion and Next Steps

Decision: Hold

Rationale:

The top-ranked prediction (HoFH) lacks a direct mechanistic link — fenofibrate's PPAR-α/triglyceride pathway does not address the LDL-receptor defect underlying HoFH — and no clinical trial has tested fenofibrate specifically in this population.
A Blocking-severity data gap (missing TFDA/label safety data) prevents this candidate from advancing to the S1 safety pre-assessment stage regardless of efficacy signal.

To proceed, the following is needed:

Retrieve and parse the official package insert (warnings, contraindications, DDI) to resolve DG001 before any S1 safety evaluation
Obtain confirmed mechanism-of-action data (DG002) to properly assess mechanistic plausibility for HoFH
Consider evaluating the rank-2 candidate ("hyperlipoproteinemia," L1 evidence, 34 clinical trials) instead, or as an interim path, since it reflects fenofibrate's already-established use rather than a novel, mechanistically unsupported indication
If HoFH remains of interest, seek preclinical or mechanistic studies directly testing fenofibrate (or fenofibrate + statin/PCSK9i combination) in LDL-receptor-deficient models before further clinical consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.